By Josh Beckerman

Eli Lilly & Co. and Incyte Corp. have provided additional data on baricitinib that indicates the drug has a "significant effect" on recovery time for Covid-19 patients.

The companies said baricitinib in combination with remdesivir reduced recovery time and improved clinical outcomes compared with remdesivir in the ACTT-2 trial. The drug had the most impact on patients requiring oxygen.

The companies, which previously said ACTT-2 met its primary endpoint, shared additional data during a virtual conference.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-08-20 1307ET